Olaparib AZD-2281 CAS 763113-22-0 Tsaftace ≥99.0% API Factory
Babban Tsafta, Samar da Kasuwanci
Olaparib da Matsakaici masu alaƙa:
Olaparib CAS 763113-22-0
2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5
2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl) benzoic acid CAS 763114-26-7
1- (Cyclopropylcarbonyl) Piperazine Hydrochloride CAS 1021298-67-8
3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9
| Sunan Sinadari | Olaparib |
| Makamantu | AZD-2281;KU0059436;Lynparza;4- (3- (4- (cyclopropanecarbonyl) piperazine-1-carbonyl) -4-fluorobenzyl) phthalazin-1 (2H) -daya;1- (Cyclopropylcarbonyl) -4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl) Methyl]-2-fluorobenzoyl] piperazin |
| Lambar CAS | 763113-22-0 |
| Lambar CAT | RF-API103 |
| Matsayin Hannun jari | A Hannun jari, Ma'aunin Samfuran Har zuwa Daruruwan Kilogram |
| Tsarin kwayoyin halitta | Saukewa: C24H23FN4O3 |
| Nauyin Kwayoyin Halitta | 434.46 |
| Solubility | Mai narkewa a cikin DMSO |
| Alamar | Ruifu Chemical |
| Abu | Ƙayyadaddun bayanai |
| Bayyanar | Fari zuwa Kashe-Farin Foda |
| Gano ta 1H NMR | Bi tsarin |
| LC-MS | Bi tsarin |
| Tsarkake / Hanyar Bincike | ≥99.0% (na LC-MS) |
| Danshi (KF) | ≤0.50% |
| Tsaftace Guda Daya | ≤0.50% |
| Jimlar ƙazanta | ≤1.0% |
| Karfe masu nauyi (kamar Pb) | ≤20ppm |
| Matsayin Gwaji | Matsayin Kasuwanci |
| Amfani | API;Mai hanawa PARP |
Kunshin: Bottle, Aluminum tsare jakar, Kwali Drum, 25kg / Drum, ko bisa ga abokin ciniki ta bukata.
Yanayin Ajiya:Ajiye a cikin kwantena da aka rufe a wuri mai sanyi da bushe;Kare daga haske da danshi.
Olaparib (CAS: 763113-22-0), mai matukar ƙarfi kuma mai hanawa PARP.A cikin Disamba 19, 2014, FDA ta amince da novel anti-cancer magani Olaparib (Lynparza) don monotherapy ga marasa lafiya na ci-gaba ciwon daji na ovarian wanda ya sha akalla 3 zagaye na chemotherapy ko marasa lafiya da ake zargi da maye gurbin BRCA.A lokaci guda, FDA ta amince da ƙididdigewa da rarraba kayan aikin bincike don gano maye gurbi a cikin BRCA1 da BRCA2, BRACAnalysis CDx.Olaparib shine magungunan hanawa na farko na PARP wanda FDA ta amince dashi.A cikin Fabrairu 2, 2015, Hukumar Kula da Abinci da Magunguna ta Tarayyar Turai (EMA) ta kuma amince Olaparib ya shiga kasuwa a cikin ƙasashe 28 na Tarayyar Turai ciki har da Iceland, Liechtenstein da Norway.Amma alamun EMA da FDA sun yarda sun ɗan bambanta;na farko shine ga shari'o'in maye gurbin kwayoyin halitta na BRCA, da kuma maganin kulawa ga marasa lafiya na ciwon daji na epithelial na ovarian wanda ya riga ya karbi maganin chemotherapy mai dauke da platinum da kuma nuna amsa da kuma batun sake dawowa.
